FDA Lifts Clinical Hold for Cellectis’s UCARTCS1 Ph1 MELANI-01 Trial; No Update on Protocol Changes
Here is a brief preview of this blast: On Tuesday, November 17, Cellectis announced (press release) that the FDA has lifted the clinical hold on their UCARTCS1 (CS1 allogeneic CAR-T) Ph1 MELANI-01 trial in r/r MM. Below, Celltelligence provides insights on the trial’s FDA mandated clinical hold and possible protocol changes.